Liver Disease Clinical Trials

Showing 241-260 of 690 trials

Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population

NCT04336618

To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting their contact information to seek interest in participating in future studies.

Non-Alcoholic Fatty Liver Disease

Perspectum67 participantsStarted Aug 2020

Dallas, Texas, United States

COMPLETEDNA

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

NCT05304455

The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection

CirrhosisSplenectomyVenous Thrombosis+1 more

Northern Jiangsu People's Hospital40 participantsStarted Apr 2022

Yangzhou, Jiangsu, China

COMPLETEDPHASE2

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200

OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

CirrhosisAscitesHepatorenal Syndrome+1 more

Ocelot Bio, Inc47 participantsStarted Apr 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +20 more locations

Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

Related Searches

Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease

A Study to Evaluate Liver Stiffness With Shear Wave Elastography

Prebiotics in Patients With Non-alcoholic Liver Disease

An Follow-Up Study of Liver Cirrhosis

Effects of Online App Weight Loss Programs on Liver Health in Obese Adults

Biomarkers in the Diagnosis and Prognosis of NAFLD

Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology

Risk Factors for Advanced Fibrosis Among FLD Patients

Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study

A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids

COVID-19 and Nonalcoholic Fatty Liver Disease

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

Regulation of FGF21 by Nutritional Challenges

Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)